Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
SC 13G

A statement of beneficial ownership of common stock by certain persons

 View HTML
0001193805-16-004164.pdf
0001193805-16-004164.rtf
0001193805-16-004164.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-030755.pdf
0001179110-16-030755.rtf
0001179110-16-030755.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-030355.pdf
0001179110-16-030355.rtf
0001179110-16-030355.xls
CT ORDER

CT ORDER

 View HTML
9999999997-16-025877.pdf
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-16-029537.pdf
0001179110-16-029537.rtf
0001179110-16-029537.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-008194.pdf
0001558370-16-008194.rtf
0001558370-16-008194.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-008088.pdf
0001558370-16-008088.rtf
0001558370-16-008088.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-16-028516.pdf
0001179110-16-028516.rtf
0001179110-16-028516.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-16-007713.pdf
0001558370-16-007713.rtf
0001558370-16-007713.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-16-007817.pdf
0001558370-16-007817.rtf
0001558370-16-007817.xls
EX-101.INS - EX-101.INS